| BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer M Xing, WH Westra, RP Tufano, Y Cohen, E Rosenbaum, KJ Rhoden, ... The Journal of Clinical Endocrinology & Metabolism 90 (12), 6373-6379, 2005 | 1228 | 2005 |
| Phase II trial of sorafenib in metastatic thyroid cancer RT Kloos, MD Ringel, MV Knopp, NC Hall, M King, R Stevens, J Liang, ... Journal of Clinical Oncology 27 (10), 1675-1684, 2009 | 667 | 2009 |
| Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer P Hou, D Liu, Y Shan, S Hu, K Studeman, S Condouris, Y Wang, A Trink, ... Clinical cancer research 13 (4), 1161-1170, 2007 | 501 | 2007 |
| Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and … Z Liu, P Hou, M Ji, H Guan, K Studeman, K Jensen, V Vasko, ... The Journal of Clinical Endocrinology & Metabolism 93 (8), 3106-3116, 2008 | 441 | 2008 |
| Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer ET Lam, MD Ringel, RT Kloos, TW Prior, MV Knopp, J Liang, S Sammet, ... Journal of Clinical Oncology 28 (14), 2323-2330, 2010 | 426 | 2010 |
| Specific Pattern of RAS Oncogene Mutations in Follicular Thyroid Tumors V Vasko, M Ferrand, J Di Cristofaro, P Carayon, JF Henry, C De Micco The Journal of Clinical Endocrinology & Metabolism 88 (6), 2745-2752, 2003 | 401 | 2003 |
| Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion V Vasko, AV Espinosa, W Scouten, H He, H Auer, S Liyanarachchi, ... Proceedings of the National Academy of Sciences 104 (8), 2803-2808, 2007 | 399 | 2007 |
| Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers T Bekaii-Saab, MA Phelps, X Li, M Saji, L Goff, JSW Kauh, BH O'Neil, ... Journal of clinical oncology 29 (17), 2357-2363, 2011 | 355 | 2011 |
| Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer V Vasko, M Saji, E Hardy, M Kruhlak, A Larin, V Savchenko, M Miyakawa, ... Journal of medical genetics 41 (3), 161-170, 2004 | 276 | 2004 |
| Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer S Hu, D Liu, RP Tufano, KA Carson, E Rosenbaum, Y Cohen, EH Holt, ... International journal of cancer 119 (10), 2322-2329, 2006 | 261 | 2006 |
| Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants X Shi, R Liu, F Basolo, R Giannini, X Shen, D Teng, H Guan, Z Shan, ... The Journal of Clinical Endocrinology 101 (1), 264-274, 2016 | 237 | 2016 |
| BRAF T1796A Transversion Mutation in Various Thyroid Neoplasms M Xing, V Vasko, G Tallini, A Larin, G Wu, R Udelsman, MD Ringel, ... The Journal of Clinical Endocrinology & Metabolism 89 (3), 1365-1368, 2004 | 167 | 2004 |
| High Prevalence and Possible de Novo Formation of BRAF Mutation in Metastasized Papillary Thyroid Cancer in Lymph Nodes V Vasko, S Hu, G Wu, JC Xing, A Larin, V Savchenko, B Trink, M Xing The Journal of Clinical Endocrinology & Metabolism 90 (9), 5265-5269, 2005 | 154 | 2005 |
| Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto’s … N Harii, CJ Lewis, V Vasko, K McCall, U Benavides-Peralta, X Sun, ... Molecular Endocrinology 19 (5), 1231-1250, 2005 | 147 | 2005 |
| AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma CS Kim, VV Vasko, Y Kato, M Kruhlak, M Saji, SY Cheng, MD Ringel Endocrinology 146 (10), 4456-4463, 2005 | 129 | 2005 |
| Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo S Thakur, B Daley, K Gaskins, VV Vasko, M Boufraqech, D Patel, ... Clinical cancer research 24 (16), 4030-4043, 2018 | 126 | 2018 |
| Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer J Klubo-Gwiezdzinska, J Costello Jr, A Patel, A Bauer, K Jensen, M Mete, ... The Journal of Clinical Endocrinology & Metabolism 98 (8), 3269-3279, 2013 | 124 | 2013 |
| Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant J Di Cristofaro, M Marcy, V Vasko, F Sebag, N Fakhry, D Wynford-Thomas, ... Human pathology 37 (7), 824-830, 2006 | 124 | 2006 |
| KiSS-1/G Protein-Coupled Receptor 54 Metastasis Suppressor Pathway Increases Myocyte-Enriched Calcineurin Interacting Protein 1 Expression and Chronically … N Stathatos, I Bourdeau, AV Espinosa, M Saji, VV Vasko, KD Burman, ... The Journal of Clinical Endocrinology & Metabolism 90 (9), 5432-5440, 2005 | 115 | 2005 |
| Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma VV Vasko, J Gaudart, C Allasia, V Savchenko, J Di Cristofaro, M Saji, ... European journal of endocrinology 151 (6), 779-786, 2004 | 112 | 2004 |
Zhi LiuJohns Hopkins University School of Medicine在 jhmi.edu 的电子邮件经过验证
